Gharpure Radhika, Vegvari Carolin, Abdissa Alemseged, Alimi Yewande, Anyamba Assaf, Auerbach Jochen, Bett Bernard, Bird Brian H, Bob Ndeye Sakha, Breugelmans J Gabrielle, Clark Jessica, Cleaveland Sarah, Cramer Jakob, Dawa Jeanette, Fay Petra C, Formenty Pierre, Gerdts Volker, Gerken Keli N, Gitonga John, Groschup Martin, Heighway James, Johnson Sherry Ama Mawuko, Juma John, Kading Rebekah C, Kamau Maureen, Kerama Samuel, Lubisi Baratang Alison, Lutwama Julius, Luyimbazi Dick, Marami Dadi, Moore Sean M, Muturi Mathew, Mwangoka Grace, Ndiu Angela, Njenga M Kariuki, Njouom Richard, Nyakarahuka Luke, Nzietchueng Serge, Oloo Paul, Otiende Mark, Oyola Samuel, Paganini Lodovico Samuele, Pandit Pranav S, Punt Carine, Samy Abdallah M, Situma Silvia, Sneddon Heidi, Ten Bosch Quirine A, Tezcan-Ulger Seda, Thompson Peter N, Tildesley Mike, Tinto Bachirou, Vesga Juan F, Wichgers Schreur Paul P, Hart Peter
Coalition for Epidemic Preparedness Innovations, Oslo, Norway, London, UK, and Washington, DC, USA.
Coalition for Epidemic Preparedness Innovations, Oslo, Norway, London, UK, and Washington, DC, USA.
Vaccine. 2025 Apr 30;54:126860. doi: 10.1016/j.vaccine.2025.126860. Epub 2025 Mar 18.
Rift Valley fever (RVF) is a zoonotic viral disease that causes epidemics and epizootics among humans and livestock, resulting in substantial health and socioeconomic consequences. Currently, there are no RVF vaccines licensed for humans, but several candidates show promise in early-stage development. Existing gaps in RVF epidemiological data and challenges associated with predicting RVF outbreak risk complicate the planning of efficacy studies, making the pathway to licensure for promising candidates unclear. In June 2024, the Coalition for Epidemic Preparedness Innovations (CEPI) convened a two-day workshop in Nairobi, Kenya, to discuss RVF epidemiology, modeling priorities, and specific gaps relevant to human RVF vaccine development. The workshop included representatives from multiple RVF-endemic countries, key global collaborators, and international health organizations. Workshop participants identified five key priorities: (1) Looking beyond outbreaks: There is a need to better characterize the complex One Health epidemiology of RVF and understand interepidemic persistence of the virus; (2) Better data for better models: Epidemiological modeling is crucial for research, prediction, and planning, but it requires accurate and representative data; (3) New, improved and accessible diagnostics and serological assays: These are needed to inform epidemiology and case definitions, without which RVF research will continue to suffer due to paucity of data and challenges in determining infection and exposure; (4) Defining use cases, regulatory pathways, and implementation strategies for human vaccines: Clarity on these topics will facilitate licensure and effective use of RVF vaccines; and (5) People-centered approaches: Community engagement and involvement of social and behavioral scientists are key to the success of human vaccine research and development and implementation, particularly as the virus impacts livestock and livelihoods. Workshop participants welcomed a renewed focus for RVF epidemiology and modeling, and expressed enthusiasm for continued multidisciplinary collaborations to support enabling sciences for human RVF vaccine research and development.
裂谷热（RVF）是一种人畜共患的病毒性疾病，可在人类和牲畜中引发流行病和 epizootics，导致严重的健康和社会经济后果。目前，尚无获批用于人类的裂谷热疫苗，但有几种候选疫苗在早期开发中显示出前景。裂谷热流行病学数据存在的现有差距以及预测裂谷热爆发风险相关的挑战，使疗效研究的规划变得复杂，使得有前景的候选疫苗的获批途径不明朗。2024年6月，流行病防范创新联盟（CEPI）在肯尼亚内罗毕召开了为期两天的研讨会，讨论裂谷热流行病学、建模重点以及与人类裂谷热疫苗开发相关的具体差距。研讨会的与会者包括来自多个裂谷热流行国家的代表、主要的全球合作伙伴以及国际卫生组织。研讨会参与者确定了五个关键重点：（1）超越疫情：需要更好地描述裂谷热复杂的“同一个健康”流行病学特征，并了解病毒在疫情间歇期的持续存在情况；（2）更好的数据用于更好的模型：流行病学建模对于研究、预测和规划至关重要，但需要准确且具有代表性的数据；（3）新型、改进且可获取的诊断和血清学检测方法：这些是了解流行病学和病例定义所必需的，没有它们，裂谷热研究将因数据匮乏以及确定感染和暴露方面的挑战而继续受阻；（4）确定人类疫苗的使用案例、监管途径和实施策略：明确这些主题将有助于裂谷热疫苗的获批和有效使用；（5）以人为本的方法：社区参与以及社会和行为科学家的参与是人类疫苗研发和实施成功的关键，尤其是因为该病毒会影响牲畜和生计。研讨会参与者对重新关注裂谷热流行病学和建模表示欢迎，并对继续开展多学科合作以支持人类裂谷热疫苗研发的支撑科学表达了热情。
